ReviewNature reviews. Gastroenterology & hepatology2011
The intestinal microbiota and chronic disorders of the gut.
Review in Nature reviews. Gastroenterology & hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 147 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison Between Lactulose and Glucose Breath Tests as Predictors of Clinical Benefit From Rifaximin in Irritable Bowel Syndrome Patients
Characterization of Rebound Pain Following Peripheral Nerve Block and Its Association With Gut Microbiome Diversity
Who cites it
147 citing papers in PubMed, 3 syntheses or guidelines pooled it, 300 citations in OpenAlex.
- Antibiotic-Associated Diarrhea BeyondThe Brown journal of hospital medicine · 2023Pooled it
- Is there a dysbiosis in individuals with a neurodevelopmental disorder compared to controls over the course of development? A systematic review.European child & adolescent psychiatry · 2021Pooled it
- Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis.Lipids in health and disease · 2021Pooled it
- Trial
- Clinical efficacy of fecal microbiota transplantation for patients with small intestinal bacterial overgrowth: a randomized, placebo-controlled clinic study.BMC gastroenterology · 2021Trial
- Putative Probiotic Strains Isolated from Kefir Improve Gastrointestinal Health Parameters in Adults: a Randomized, Single-Blind, Placebo-Controlled Study.Probiotics and antimicrobial proteins · 2020Trial
- Dysbiosis of fungal microbiota in the intestinal mucosa of patients with colorectal adenomas.Scientific reports · 2015Trial
- Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.American journal of therapeuticsTrial
- High-throughput analyses ofGut microbes · 2026Article
- Review
- Prebiotics, Probiotics, and Gut Microbiota with Chronic Disease (2nd Edition): Advances, Challenges, and Future Perspectives.Nutrients · 2026Article
- Microbial Monotherapy With Leuconostoc sp LB-P8 Improves Inflammation and Fibrosis in Mouse Primary Sclerosing Cholangitis by Inhibiting Transforming Growth Factor β1/SMAD Signaling.Cellular and molecular gastroenterology and hepatology · 2026Article
- The Impact of Imidacloprid in Dietary Residues on Intestinal Damage and the Increased Risk of EnterotoxigenicFoods (Basel, Switzerland) · 2025Article
- Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease.Frontiers in microbiology · 2025Review
- Article
- Comparative analysis of composition and spatial variations in the foregut microbiota of male and female donkeys.Frontiers in microbiology · 2025Article
- Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: Risk Management and Surveillance Strategies.Cancers · 2024Review
- Predicting potential microbe-disease associations based on dual branch graph convolutional network.Journal of cellular and molecular medicine · 2024Article
- Breaking barriers: bacterial-microalgae symbiotic systems as a probiotic delivery system.Journal of nanobiotechnology · 2024Article
- Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.Journal of gastroenterology · 2024Article
87 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal surfaces of the gut are colonized by large numbers of heterogeneous bacteria that contribute to intestinal health and disease. In genetically susceptible individuals, a 'pathogenic community' may arise, whereby abnormal gut flora contributes to alterations in the mucosa and local immune system leading to gastrointestinal disease. These diseases include enteric infections, such as Clostridium difficile infection, small intestinal bacterial overgrowth, functional gastrointestinal disorders (including IBS), IBD and colorectal cancer. Prebiotics, probiotics and synbiotics (a combination of prebiotics and probiotics) have the capacity to reverse pathologic changes in gut flora and local immunity. Intestinal health and disease need to be thoroughly characterized to understand the interplay between the indigenous microbiota, the immune system and genetic host factors. This Review provides a broad overview of the importance of the intestinal microbiota in chronic disorders of the gut.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.